



Ap 1646

PATENT
Client-Matter No.: 66778-120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Group Art Unit: 1646
Ingraham and Krylova)
Serial No.: 10/616,897)
Filed: July 9, 2003)
For: STEROIDOGENIC FACTOR-1)
PROTEIN VARIANTS AND)
METHODS OF MAKING)
SAME)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on November 20, 2003.

By: Andrea L. Gashler
Andrea L. Gashler, Reg. No. 41,029

November 20, 2003
Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 502624.

Respectfully submitted,

Date: November 20, 2003

Andrea L. Gashler

Andrea L. Gashler
Registration No.: 41,029
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

 US Department of Commerce Patent and Trademark Office	ATTY CLIENT- MATTER NO:	SERIAL NO.
	66778-120	10/616,897
APPLICANT: Ingraham and Krylova		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 9, 2003	GROUP: 1646

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
		4,959,314	9/25/90	Mark et al.	435	69.1	2/7/85

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Crawford et al., "The Activation Function-2 Hexamer of Steroidogenic Factor-1 Is Required, but Not Sufficient for Potentiation by SRC-1," <u>Mol. Endocrinol.</u> 11:1626-1635 (1997).
	Egea et al., "Crystal structure of the human RXR α ligand-binding domain bound to its natural ligand: 9-cis retinoic acid," <u>EMBO J.</u> 19:2592-2601 (2000).
	Evans, "The Steroid and Thyroid Hormone Receptor Superfamily," <u>Science</u> 240:889-895 (1988).
	Forman et al., "Androstanone metabolites bind to and deactivate the nuclear receptor CAR- β ," <u>Nature</u> 395:612-615 (1998).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: 66778-120	SERIAL NO. 10/616,897
	APPLICANT: Ingraham and Krylova	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 9, 2003	GROUP: 1646

	Gangloff et al., "Crystal Structure of a Mutant hER α Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism," <u>J. Biol. Chem.</u> 276:15059-15065 (2001).
	Geistlinger and Guy, "An Inhibitor of the Interaction of Thyroid Hormone Receptor β and Glucocorticoid Interacting Protein 1," <u>J. Am. Chem. Soc.</u> 123:1525-1526 (2001).
	Hammer and Ingraham, "Steroidogenic Factor-1: Its Role in Endocrine Organ Development and Differentiation," <u>Front. Neuroendocrinol.</u> 20: 199-223 (1999).
	Hammer et al., "Phosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment: Integration of Hormone Signaling in Reproduction and Stress," <u>Mol. Cell.</u> 3:521-526 (1999).
	Ikeda et al., "Characterization of the Mouse FTZ-F1 Gene, Which Encodes a Key Regulator of Steroid Hydroxylase Gene Expression," <u>Mol. Endocrinol.</u> 7:852-860 (1993).
	Ito et al., "DAX-1 Inhibits SF-1-Mediated Transactivation via a Carboxy-Terminal Domain That Is Deleted in Adrenal Hypoplasia Congenita," <u>Mol. Cell Biol.</u> 17:1476-1483 (1997).
	Lala et al., "Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols," <u>Proc. Natl. Acad. Sci. USA</u> 94:4895-4900 (1997).
	Lala et al., "Steroidogenic Factor I, a Key Regulator of Steroidogenic Enzyme Expression, Is the Mouse Homolog of <i>fushi tarazu</i> -Factor I," <u>Molecular Endocrinology</u> 6:1249-1258 (1992).
	Li et al., "Cloning and Characterization of a Novel Human Hepatocyte Transcription Factor, hB1F, Which Binds and Activates Enhancer II of Hepatitis B Virus," <u>J. Biol. Chem.</u> 273:29022-29031 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1646 U.S. Patent & Trademark Office	ATTY DOCKET NO:	SERIAL NO.
	66778-120	10/616,897
	APPLICANT: Ingraham and Krylova	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: July 9, 2003	GROUP: 1646

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.